| FIRST AUTHOR INDEX |
| Last Name |
First Name |
No. |
Title |
| MIYAKE |
Nobumi |
O-02
|
Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: A randomized double-blind comparison with risperidone. |
| Ishii |
K |
O-04 |
Efficacy and safety of twice a day administration of perospirone for patients with schizophrenia. |
| Nakane |
Hideyuki |
O-06 |
Validity and Safety of Olanzapine-Zydis to acute symptoms of schizophrenia - Nagasaki Zydis investigate group Final report - |
| Harada |
Toshiki |
O-08 |
Four cases of oral dyskinesia during quetiapine treatment |
| Isotani |
Toshiaki |
O-10 |
Evaluation of aripiprazole treatment for schizophrenic patients |
| Kosaka |
Takamitsu |
O-14 |
Efficacy of Supplemental food containing Guarana for cognitive functional disorder in schizophrenia. |
| Yoshimura |
Reiji |
O-19 |
Effects of SSRI or SNRI on blood levels of brain-derived neurotrophic factor and cytokines in depressed patients |
| Moritoki |
Yukihiro |
O-23 |
A case of OCD with prolonged aggressiveness and impulsivity apparently related to activation syndrome even after discontinuation of paroxetine |
| Yoshimura |
Reiji |
O-24 |
Effects of atypical antipsychotic drugs addition to antidepressants for refractory depression |
| Watanabe |
Junzo |
O-26 |
Effect of atypical antipsychotic agents on the QT interval: using ambulatory electrocardiographic (Holter) recording |
| Sukegawa |
Tsuruhei |
O-30 |
The relationship between the administration of antihypotensives and survival rate on inptients with schizophrenia |
| Sugita |
Atsuko |
O-31 |
Brain derived neurotrophic factor is associated with disease severity of neuropsychiatric systemic lupus erythematosus |
| Hokyo |
Akira |
O-39 |
The Clinical study of schizophrenia treatment by using the third generation antipsychotic; Aripiprazole |
| Hikaru Hori |
Hikaru Hori |
O-42 |
Effect of aripiprazole on plasma levels of catecholamine metabolites and brain-derived neurotriphic factor in schizophrenic patients |
| Fukui |
Naoki |
O-44 |
Association between D2 dopamine receptor gene polymorphism and extreme hyperprolactinemia induced by antipsychotics |
| Sawamura |
Kazushi |
O-46 |
Relationship between olanzapine-induced weight gain and SNP45T/G polymorphism in the adiponectin gene |
| Uchida |
Naoki |
O-48 |
Salivary cortisol and dehydroepiandrosterone in depressive patients |
| Suga |
Hidemichi |
O-49 |
A study of 1-year follow-up after ECT for patients with refractory depression. |
| Uemura |
Keiichi |
O-50 |
Efficacy and safety of low dose sulpiride treatment in patients with bipolar depression: A retrospective study |
| Jitsuiki |
Hiroaki |
O-51 |
Serum Valproate Levels in Maintenance Therapy for Bipolar Disorder in Japan |
| Umene |
Wakako |
O-53 |
Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham’s chorea |
| Shimizu |
Yoshio |
O-54 |
A case of specific phobia against her mother-in-law improved by paroxetine |
| Ota |
Tomoo |
O-55 |
Lithium (Li) augmentation to valproate (VPA) for paraneoplastic limbic encephalitis (PLE) with agitation: a case report. |
| Egami |
Hideaki |
O-56 |
Two adolescent cases of abnormal behavior to zolpidem administration |
| Ono |
Hisae |
P-02 |
A Study Examining Pharmacokinetics of Rapid Acting Intra-muscular Olanzapine in Japanese Agitated Patients with Schizophrenia |
| Ogino |
Shin |
P-03 |
Subjective Well-being in Schizophrenic Patients: A Four-group Comparison of Aripiprazole, Olanzapine, Risperidone, and Low-dose Haloperidol |
| Endo |
Takako |
P-04 |
Survey of Antipsychotic Medications Prescribed for Concomitant Use by Schizophrenia Patients Being Treated with Olanzapine |
| Kuramochi |
Motoki |
P-05 |
The efficacy and safety of olanzapine in acute schizophrenic patients : The interim analysis of a post marketing surveillance. |
| Yoshimura |
N. |
P-10 |
A comparison of efficacy and safety of risperidone,olanzapine,haloperidol and quetiapine for the treatment of acute agitation in patients with schizophrenia. |
| Hashimoto |
Naoki |
P-18 |
A 26 week outcome of the switching to the aripiprazole in 86 schizophrenia patients. |
| Kuramochi |
Motoki |
P-23 |
Effects of olanzapine on health outcome in patients with schizophrenia |
| Nishiuma |
Shinichi |
P-24 |
Final Report of the Postmarketing Prospective Study in Patients with Schzophrenia using Olanzapine |
| Kamei |
Hiroyuki |
P-27 |
Association between the severity of symptoms and illness insight/medication adherence in patients with schizophrenia |
| Utagawa |
Itaru |
P-28 |
Prescriptions Written for Schizophrenia Outpatients |
| Ono |
Hisae |
P-33 |
Reliability Testing of the Japanese Version of Agitation-Calmness Evaluation Scale（ACES©） |
| Kikuyama |
Hiroki |
P-34 |
Effects of the serotonin transporter gene polymorphism on risperidone and perospirone efficacy and adverse events in schizophrenia. |
| Kanazawa |
Tetsufumi |
P-35 |
Effects of the DRD2 gene polymorphism on risperidone and perospirone efficacy and adverse events in schizophrenia. |
| Tsutsumi |
Atsushi |
P-36 |
Effects of the DRD4 gene polymorphism on risperidone and perospirone in schizophrenia. |
| Utsunomiya |
Kensuke |
P-39 |
No association between the dopamine D1 receptor gene (DRD1) polymorphism (-48A/G) and polydipsia in schizophrenia |
| Sakata |
Shinichi |
P-40 |
Association analysis between the HTR2A gene polymorphism (T102C) and polydipsia in schizophrenia |
| Shinkai |
Takahiro |
P-41 |
No association between TPH2 polymorphisms and polydipsia in schizophrenia |
| Inoue |
Yoshiaki |
P-43 |
Association analysis between the functional -485C>T polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia |
| Furuya |
Motohide |
P-47 |
Successful adjunctive treatment of Yi-Gan San for schizophrenia : A case report |
| Murata |
Yusuke |
P-50 |
Discontinuation Syndrome Associated with Paroxetine : A Clinical and Pharmacogenetic research |
| Takahashi |
Hidetoshi |
P-57 |
Effect of sertraline hydrochloride on prepulse inhibition and habituation of the acoustic startle startle reflex in patients with major depressive disorder; a preliminary study. |
| Okuda |
Akiko |
P-59 |
Necessity of early treatment of major depressive disorder.（The second report）-Prognosis and therapeutic response- |
| Yamada |
Kazuo |
P-60 |
New idea in the evidence-based guideline for treatment of bipolar depression in Japan |
| Kurumaji |
Akeo |
P-61 |
A clinical study of additive treatment with mood stabilizers on the inpatients with depressive disorders. |
| Iwamoto |
Kunihiro |
P-66 |
The effects of acute treatment with antidepressants on driving performance and cognitive function in healthy Japanese subjects |
| Wada |
Ken |
P-68 |
Two-year outcome of unipolar depression patients with manic or hypomanic switch during acute antidepressant treatment |
| Miyamoto |
Ayumu |
P-71 |
A patient with major depressive disorder combined with neuroleptic malignant syndrome caused by amoxapine |
| Naitoh |
Hiroshi |
P-75 |
Drug-induced hypersensitivity syndrome in a patient with bipolar II disorder on sodium valproate therapy. |
| Sawada |
Masayuki |
P-83 |
A case of adolescent patient with obsessive-compulsive disorder effectively treated by fluvoxamine and olanzapine |
| Kokubo |
Yosuke |
P-85 |
Drug treatment of panic disorder: the comparison between 1994-1996 and 2004-2006 |
| Yoshida |
Takafumi |
P-86 |
Tandospirone augmentation of serotonin reuptake inhibitors for anxiety disorder: three cases |
| Shiozaki |
Kazumasa |
P-91 |
“Improvement of hallucination and delusion as BPSD after donepezil administration in a case with Alzheimer’s disease” |
| Kishimoto |
Makiko |
P-94 |
A case report of recurrent SSRI discontinuation syndrome with fasciculation and high CPK value |
| Endo |
Go |
P-95 |
A case of acute mandibular dystonia induced by concomitant administration of perospirone and clarithromycin |
| Obara |
Yoshihiko |
P-96 |
A case of nightmare improved markedly by risperidone |
| Hori |
Hikaru |
PA-1 |
Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients |
| Okugawa |
Gaku |
S1-4 |
Perospirone clinical comparison with risperidone |
| Miyamoto |
Seiya |
S1-5 |
Current position of aripiprazole and its future prospects |
| Okada |
Takashi |
S2-3 |
Pharmacotherapy for Children and Adolescents with Pervasive Developmental Disorders |
| Iida |
Junzo |
S2-4 |
Pharmacotherapy of children with Attention-Deficit/Hyperactivity Disorder |
| Suhara |
Tetsuya |
S3-2 |
Early Investigational New Drug for CNS using Positron Emission Tomography |
| Ishii |
Ryouhei |
S3-4 |
Source localizations of EEG oscillatory activity in association with plasma concentrations of antiepileptic drugs |
| Tajima |
Osamu |
S4-1 |
Pharmacologic Profile of Fluvoxamine and its Implication in the Treatment of Depression and Anxiety Disorders |
| Inoue |
Takeshi |
S4-3 |
Unique characteristics of sertraline |
| Sakamoto |
Kaoru |
S4-4 |
Proper Use of New Antidepressants - Focusing upon Differentiation between Milnacipran and SSRIs - |
| Honda |
Mari |
S5-4 |
Consideration of clinical trial with placebo: double-blind placebo-controlled trial for Schizophrenia |
